BR0313113A - Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina - Google Patents
Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacinaInfo
- Publication number
- BR0313113A BR0313113A BR0313113A BR0313113A BR0313113A BR 0313113 A BR0313113 A BR 0313113A BR 0313113 A BR0313113 A BR 0313113A BR 0313113 A BR0313113 A BR 0313113A BR 0313113 A BR0313113 A BR 0313113A
- Authority
- BR
- Brazil
- Prior art keywords
- infectious
- replicon
- pestivirus
- virus
- replicons
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title abstract 7
- 230000002458 infectious effect Effects 0.000 title abstract 7
- 241000710778 Pestivirus Species 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002245 particle Substances 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 4
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 abstract 3
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 abstract 3
- 101710172711 Structural protein Proteins 0.000 abstract 3
- 101710117545 C protein Proteins 0.000 abstract 2
- 210000002845 virion Anatomy 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 241001068263 Replication competent viruses Species 0.000 abstract 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 abstract 1
- 230000010530 Virus Neutralization Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24341—Use of virus, viral particle or viral elements as a vector
- C12N2770/24343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24361—Methods of inactivation or attenuation
- C12N2770/24362—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"REPLICON DE UM PESTIVIRUS, PARTìCULA VIRAL INFECCIOSA DE PESTIVìRUS, MéTODO PARA A PRODUçãO DA MESMA, E, VACINA". A presente invenção provê novos genomas de RNA pestivirais (replicons) que são capazes de replicar, e podem ser embalados em particulas virais infecciosas em células que complementam a(s) proteína(s) faltando, mas não produzem virus de progênie infecciosos. Estes replicons podem ser usados para fins de vacina. Os replicons codificam a maior parte, preferivelmente todas, as proteinas de envelope do virus, enquanto, por outro lado,, não podem ser capazes de produzir vírus de progênie infecciosos. A presente invenção provê um replicon pestiviral, preferivelmente de virus de diarréia viral bovina (BVDV) que expressa todas as proteinas estruturais exceto por uma proteina C ou E1 funcional. Preferivelmente, pelo menos parte da seq³ência de codificação da proteína E1 ou C foi deletada do referido replicon. Os presentes inventores provaram, pela primeira vez, que ambas as proteinas estruturais C e E1 são essenciais para a formação de pestivírus infecciosos. Além disso, foi demonstrado que a deleção de C e E1 não impacta a capacidade de RNA de auto-replicação. Ao usar linhagens de células expressando constitutivamente proteínas estruturais pestivirais, as proteínas de capsídeo ou E1 podem ser eficazmente trans-complementadas. Os vírions resultantes são capazes de infectar as células de marcação bovinas e transferir os replicons sem gerar progênie de vírus competentes para replicação. Em outras palavras, não se produz um vírus de progênie infeccioso. Os vírions complementados são indistinguíveis de Pestivirus de tipo selvagem em experiências de neutralização de virus. Os vírus complementados podem ser usados para a imunização segura e eficaz contra BVDV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02078357 | 2002-08-13 | ||
| PCT/EP2003/009031 WO2004016794A1 (en) | 2002-08-13 | 2003-08-12 | Replicons of pestiviruses that do not express c and or e1 protein and infectious viral particles containing same, that can be used in vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0313113A true BR0313113A (pt) | 2005-06-28 |
Family
ID=31725452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0313113A BR0313113A (pt) | 2002-08-13 | 2003-08-12 | Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US7244434B2 (pt) |
| EP (1) | EP1534846A1 (pt) |
| JP (1) | JP4664072B2 (pt) |
| AU (1) | AU2003258611A1 (pt) |
| BR (1) | BR0313113A (pt) |
| CA (1) | CA2495294C (pt) |
| MX (1) | MXPA05001644A (pt) |
| WO (1) | WO2004016794A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT410634B (de) * | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
| JP2006071631A (ja) * | 2004-08-06 | 2006-03-16 | Bl:Kk | フラビウイルス科ペスチウイルス属ウイルスの検出法およびそのイムノクロマトグラフィーにおける使用 |
| EA016490B1 (ru) * | 2006-02-27 | 2012-05-30 | Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем | Псевдоинфекционный флавивирус и его применение |
| US8394620B2 (en) * | 2007-05-07 | 2013-03-12 | The Board Of Regents Of The University Of Texas System | Two-component genome flavivirus and uses thereof |
| WO2009098277A1 (en) | 2008-02-08 | 2009-08-13 | Intercell Ag | Flaviviridae mutants comprising a deletion in the capsid protein for use as vaccines |
| EP2130912A1 (en) * | 2008-06-04 | 2009-12-09 | Institut für Viruskrankeiten und Immunprophylaxe | Pestivirus replicons providing an RNA-based viral vector system |
| IL294290A (en) | 2019-12-31 | 2022-08-01 | Elixirgen Therapeutics Inc | Transient temperature-based delivery of nucleic acids and proteins to cells and tissues |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995035380A1 (en) * | 1994-06-17 | 1995-12-28 | Instituut Voor Dierhouderij En Diergezondheid | Nucleotide sequences of pestivirus strains, polypeptides encoded by these sequences and use thereof for diagnosis and prevention of pestivirus infections |
| EP1035205A1 (en) * | 1999-03-08 | 2000-09-13 | Stichting Dienst Landbouwkundig Onderzoek | Non-spreading pestivirus |
| EP1104676A1 (en) | 1999-11-30 | 2001-06-06 | Boehringer Ingelheim Vetmedica Gmbh | Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
| ES2261329T3 (es) * | 2000-04-21 | 2006-11-16 | Akzo Nobel N.V. | Mutantes de pestivirus y vacunas que los contienen. |
| AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
-
2003
- 2003-08-12 US US10/524,210 patent/US7244434B2/en not_active Expired - Fee Related
- 2003-08-12 BR BR0313113A patent/BR0313113A/pt not_active Application Discontinuation
- 2003-08-12 EP EP03787795A patent/EP1534846A1/en not_active Withdrawn
- 2003-08-12 CA CA2495294A patent/CA2495294C/en not_active Expired - Fee Related
- 2003-08-12 WO PCT/EP2003/009031 patent/WO2004016794A1/en not_active Ceased
- 2003-08-12 JP JP2004528496A patent/JP4664072B2/ja not_active Expired - Fee Related
- 2003-08-12 AU AU2003258611A patent/AU2003258611A1/en not_active Abandoned
- 2003-08-12 MX MXPA05001644A patent/MXPA05001644A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2495294C (en) | 2012-06-12 |
| US7244434B2 (en) | 2007-07-17 |
| MXPA05001644A (es) | 2005-04-19 |
| EP1534846A1 (en) | 2005-06-01 |
| CA2495294A1 (en) | 2004-02-26 |
| JP2005535338A (ja) | 2005-11-24 |
| US20050208071A1 (en) | 2005-09-22 |
| JP4664072B2 (ja) | 2011-04-06 |
| WO2004016794A1 (en) | 2004-02-26 |
| AU2003258611A1 (en) | 2004-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Novoa et al. | Virus factories: associations of cell organelles for viral replication and morphogenesis | |
| Kofler et al. | Capsid protein C of tick-borne encephalitis virus tolerates large internal deletions and is a favorable target for attenuation of virulence | |
| Pushko et al. | Replicon-helper systems from attenuated venezuelan equine encephalitis virus: Expression of heterologous genesin vitroand immunization against heterologous pathogensin vivo | |
| Liao et al. | Effect of enforced expression of human bcl-2 on Japanese encephalitis virus-induced apoptosis in cultured cells | |
| CY1116491T1 (el) | Εμβολιο εναντι του αφθωδους πυρετου | |
| Holmblat et al. | Nonhomologous recombination between defective poliovirus and coxsackievirus genomes suggests a new model of genetic plasticity for picornaviruses | |
| BR0113307A (pt) | Molécula de proteìna quimérica de núcleo de vìrus de hepatite b recombinante, partìcula imunogênica, vacina ou inóculo, ácido nucleico, molécula de ácido nucleico recombinante, célula hospedeira e método de induzir uma resposta imunológica em um animal hospedeiro inoculado | |
| DK1294892T3 (da) | Aggregering af vildtype- og kimære influenzaviruslignende partikler (VLP'er) | |
| EP0835315A4 (en) | VACCINE AGAINST THE VIRUS RESPONSIBLE FOR RESPIRATORY AND REPRODUCTION DISEASES IN PIGS | |
| LU91392I2 (fr) | "La particule viroïde de la protéine L1 recombinante du papillomavirus humain de type 16" - Cervarix | |
| BR0313113A (pt) | Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina | |
| RU2009145104A (ru) | Флавивирус с двухкомпонентным геномом и его использование | |
| JP2010527593A5 (pt) | ||
| Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
| ATE404582T1 (de) | Immunogene zusammensetzungen, die replikonvektoren des venezolanischen pferdeencephalitisvirus und paramyxovirus- proteinantigene enthalten | |
| Hidajat et al. | Next generation sequencing of DNA-launched Chikungunya vaccine virus | |
| WO2000022137A3 (en) | Selectively replicating viral vectors | |
| MXPA02012593A (es) | Particulas de tipo virus del virus de la diarrea viral bovina. | |
| ES2637629T3 (es) | Inducción de una respuesta inmunitaria frente al virus del dengue usando un enfoque de sensibilización-refuerzo | |
| Kim et al. | Generation of VHSV replicon particles carrying transmembrane and C-terminal cytoplasmic region-deleted G gene (rVHSV-GΔTM) and comparison of vaccine efficacy with G gene-deleted VHSV (rVHSV-ΔG) | |
| AR051923A1 (es) | Secuencias de acidos nucleicos que codifican proteinas capaces de asociarse en particulas tipo virus | |
| Van Gennip et al. | Structural protein VP2 of African horse sickness virus is not essential for virus replication in vitro | |
| AR041515A1 (es) | Vacuna a dna contra el virus de papiloma humano | |
| US11154607B2 (en) | Genetically attenuated nucleic acid vaccine | |
| Terry et al. | The construction of defective interfering rubella virus particles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: INTERVET INTERNATIONAL B.V. (NL) Free format text: TRANSFERIDO DE: AKZO NOBEL N.V. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13, 10 E 25 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |